Abstract
The term autoimmune pancreatitis (AIP) was first used by Yoshida et al. in 1995 to describe a chronic pancreatitis characterized by autoimmune manifestations on laboratory, histopathological and clinical testing [1]. While initial descriptions of the clinical entity arose primarily in Japan, a growing awareness of the condition has led to reports around the world. The fact that AIP has presented so recently as a new clinical entity in gastroenterology is remarkable, while its protean pancreaticobiliary and systemic presentations foster the disease’s unique position within gastrointestinal pathology.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
